KSHV transactivator-derived small peptide traps coactivators to attenuate MYC and inhibits leukemia and lymphoma cell growth

Shimoda et al. present evidence that a small functional peptide derived from the KSHV transactivator could be used to target MYC in cancer. The authors find that the peptide attenuates MYC expression, reduces cell proliferation, and selectively kills cancer cells in tissue culture and a xenograft tu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Michiko Shimoda, Yuanzhi Lyu, Kang-Hsin Wang, Ashish Kumar, Hiroki Miura, Joshua F. Meckler, Ryan R. Davis, Chanikarn Chantarasrivong, Chie Izumiya, Clifford G. Tepper, Ken-ichi Nakajima, Joseph Tuscano, Gustavo Barisone, Yoshihiro Izumiya
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Acceso en línea:https://doaj.org/article/eaec3f23d40d4e7a83a5c5ddca22da0a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Shimoda et al. present evidence that a small functional peptide derived from the KSHV transactivator could be used to target MYC in cancer. The authors find that the peptide attenuates MYC expression, reduces cell proliferation, and selectively kills cancer cells in tissue culture and a xenograft tumor mouse model, by blocking recruitment of coactivator complexes (Nuclear receptor coactivator 2, p300, and SWI/SNF proteins) to the MYC promoter.